In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read More
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...
Read More
In a nutshell This study looks at the effectiveness of acalabrutinib (Calquence) to treat patients with relapsed or refractory mantle cell lymphoma. The study concluded that acalabrutinib is a safe and effective treatment for relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is an aggressive...
Read More
In a nutshell This study looked at the use of axicabtagene ciloleucel (axi-cel) treatment for patients with difficult to treat diffuse large B-cell lymphoma. The study concluded that axi-cel is an effective treatment for diffuse large B-cell lymphoma. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type of...
Read More
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...
Read More
In a nutshell This study determined the effectiveness and safety of brentuximab vedotin (Adcetris) administered with AVD (doxorubicin, vinblastine, dacarbazine) chemotherapy for stage 3 or 4 classical HL (Hodgkin’s lymphoma). The study concluded that brentuximab vedotin with AVD was more effective than ABVD (AVD plus bleomycin). Some...
Read More
In a nutshell This study investigated the effects of abexinostat in patients with relapsed or refractory (did not respond to treatment) NHL (non-Hodgkin’s lymphoma). The study concluded that abexinostat is safe and effective in patients with NHL (particularly follicular lymphoma and diffuse large B-cell lymphoma). Some background Histone...
Read MoreIn a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...
Read More
In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...
Read More
In a nutshell This review explores the current treatments for patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma. Patients with relapsed MCL generally have poor outcomes. These patients with relapsed or difficult to treat (refractory) MCL have...
Read MoreIn a nutshell This study examined the effectiveness of lenalidomide (Revlimid) in patients with mantle cell lymphoma (MCL) already treated with ibrutinib (Imbruvica). The authors concluded that lenalidomide was effective following ibrutinib. Some background There is no standard-of-care treatment for patients with relapsed or refractory (did not...
Read More
In a nutshell The aim of this trial is to determine how patients with advanced, hormone-resistant prostate cancer with evidence of a homologous recombination gene deficiency respond to rucaparib (Rubraca) treatment. The main outcome to be measured is the response to treatment, and changes to prostate-specific antigen levels (a protein present in...
Read More
